A Phase II Irinotecan-cisplatin Combination in Advanced Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2003 Nov 13

PMID 14612893

Authors

C Markham

D D Stocken

A B Hassan

Affiliations

Soon will be listed here.

Abstract

We report a cisplatin and irinotecan combination in patients with biopsy-proven advanced pancreatic adenocarcinoma. Patients were selected from a specialist centre and required good performance status (KPS>70%), measurable disease on CT scan, and biochemical and haematological parameters within normal limits. Based on a two-stage phase II design, we aimed to treat 22 patients initially. The study was stopped because of the death of the 19th patient during the first treatment cycle, with neutropenic sepsis and multiorgan failure. A total of 89 treatments were administered to 17 patients. Serious grade 3/4 toxicities were haematological (neutropenia) 6%, diarrhoea 6%, nausea 7% and vomiting 6%. Using the clinical benefit response (CBR) criteria, no patients had an overall CBR. For responses confirmed by CT examination, there was one partial response (5%), three stable diseases lasting greater than 6 weeks (16%), with an overall 22% with disease control (PR+SD). The median progression-free and overall survival was 3.1 months (95% CI: 1.3-3.7) and 5.0 (95% CI: 3.9-10.1) months, respectively. Although this synergistic combination has improved the response rates and survival of other solid tumours, we recommend caution when using this combination in the palliation of advanced pancreatic cancer, because of unexpected toxicity.

References

Cunningham D, Glimelius B . A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol. 1999; 26(1 Suppl 5):6-12. View

Ahlgren J . Chemotherapy for pancreatic carcinoma. Cancer. 1996; 78(3 Suppl):654-63. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<654::AID-CNCR46>3.0.CO;2-V. View

Rothenberg M, Cox J, DeVore R, Hainsworth J, Pazdur R, Rivkin S . A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999; 85(4):786-95. View

Cascinu S, Silva R, Barni S, Labianca R, Frontini L, Piazza E . A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 1999; 80(10):1595-8. PMC: 2363090. DOI: 10.1038/sj.bjc.6690568. View

Kozuch P, Grossbard M, Barzdins A, Araneo M, Robin A, Frager D . Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist. 2001; 6(6):488-95. DOI: 10.1634/theoncologist.6-6-488. View

Takeda S, Shimazoe T, Kuga H, Sato K, Kono A . Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. Biochem Biophys Res Commun. 1992; 188(1):70-7. DOI: 10.1016/0006-291x(92)92351-w. View

Evans T, Lofts F, Mansi J, Glees J, Dalgleish A, Knight M . A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer. 1996; 73(10):1260-4. PMC: 2074505. DOI: 10.1038/bjc.1996.241. View

Bramhall S, Rosemurgy A, Brown P, Bowry C, Buckels J . Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001; 19(15):3447-55. DOI: 10.1200/JCO.2001.19.15.3447. View

WHITEHEAD R, Jacobson J, Brown T, Taylor S, Weiss G, Macdonald J . Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1997; 15(6):2414-9. DOI: 10.1200/JCO.1997.15.6.2414. View

10.

De Jonge M, Verweij J, de Bruijn P, Brouwer E, Mathijssen R, van Alphen R . Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol. 2000; 18(1):195-203. DOI: 10.1200/JCO.2000.18.1.195. View

11.

Andreyev H, Norman A, Oates J, Cunningham D . Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?. Eur J Cancer. 1998; 34(4):503-9. DOI: 10.1016/s0959-8049(97)10090-9. View

12.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

13.

Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H . In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res. 2001; 7(1):202-9. View

14.

Bissery M, Vrignaud P, Lavelle F, Chabot G . Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs. 1996; 7(4):437-60. DOI: 10.1097/00001813-199606000-00010. View

15.

Gandia D, Abigerges D, Armand J, Chabot G, Da Costa L, De Forni M . CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol. 1993; 11(1):196-7. DOI: 10.1200/JCO.1993.11.1.196. View

16.

Wagener D, Verdonk H, Dirix L, Catimel G, Siegenthaler P, Buitenhuis M . Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995; 6(2):129-32. DOI: 10.1093/oxfordjournals.annonc.a059107. View

17.

Rothenberg M, Abbruzzese J, Moore M, Portenoy R, Robertson J, Wanebo H . A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996; 78(3 Suppl):627-32. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y. View

18.

Slater S, Shamash J, Wilson P, Gallagher C, Slevin M . Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. Br J Cancer. 2002; 87(8):850-3. PMC: 2376181. DOI: 10.1038/sj.bjc.6600553. View

19.

Mathijssen R, Verweij J, de Jonge M, Nooter K, Stoter G, Sparreboom A . Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol. 2002; 20(1):81-7. DOI: 10.1200/JCO.2002.20.1.81. View

20.

Wigmore S, Plester C, Richardson R, Fearon K . Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997; 75(1):106-9. PMC: 2222706. DOI: 10.1038/bjc.1997.17. View